Technical Analysis for PHASQ - Phasebio Pharmaceuticals Inc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Narrow Range Bar | Range Contraction | 8.84% | |
| Inside Day | Range Contraction | 8.84% | |
| Wide Bands | Range Expansion | 8.84% | |
| Fell Below 20 DMA | Bearish | 11.89% | |
| Fell Below 50 DMA | Bearish | 11.89% | |
| 180 Bearish Setup | Bearish Swing Setup | 11.89% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 7 days ago |
| Up 5% | 7 days ago |
| Up 3% | 7 days ago |
| Up 10% | 7 days ago |
| Up 2% | 7 days ago |
Get a Trading Sidekick!
Phasebio Pharmaceuticals Inc Description
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Biopharmaceutical Medication Organic Compounds U.S. Bankruptcy Court Chemical Compounds Alcohols U.S. Bankruptcy Court For The District Of Delaware Cardiovascular Diseases Astrazeneca Cyclopropanes Pulmonary Arterial Hypertension Invasive Procedure Pulmonary Hypertension
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Date | Title |
|---|
| Indicator | Value |
|---|---|
| 52 Week High | 0.139 |
| 52 Week Low | 0.01 |
| Average Volume | 513,059 |
| 200-Day Moving Average | 0.0000 |
| 50-Day Moving Average | 0.0338 |
| 20-Day Moving Average | 0.0283 |
| 10-Day Moving Average | 0.0179 |
| Average True Range | 0.0182 |
| RSI | 45.05 |
| ADX | 29.83 |
| +DI | 30.4091 |
| -DI | 11.6444 |
| Chandelier Exit (Long, 3 ATRs) | 0.0354 |
| Chandelier Exit (Short, 3 ATRs) | 0.0646 |
| Upper Bollinger Bands | 0.0637 |
| Lower Bollinger Band | -0.0071 |
| Percent B (%b) | 0.33 |
| BandWidth | 250.1767 |
| MACD Line | -0.0064 |
| MACD Signal Line | -0.0066 |
| MACD Histogram | 0.0003 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.0180 | ||||
| Resistance 3 (R3) | 0.0177 | 0.0169 | 0.0176 | ||
| Resistance 2 (R2) | 0.0169 | 0.0164 | 0.0170 | 0.0175 | |
| Resistance 1 (R1) | 0.0164 | 0.0161 | 0.0167 | 0.0167 | 0.0174 |
| Pivot Point | 0.0156 | 0.0156 | 0.0157 | 0.0157 | 0.0156 |
| Support 1 (S1) | 0.0151 | 0.0151 | 0.0154 | 0.0154 | 0.0146 |
| Support 2 (S2) | 0.0143 | 0.0148 | 0.0144 | 0.0145 | |
| Support 3 (S3) | 0.0138 | 0.0143 | 0.0144 | ||
| Support 4 (S4) | 0.0141 |
